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The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and
updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which
has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al.
Consensus on medical treatment of non-small-cell lung cancer—update 2004. Lung Cancer 2005; 50: 129–137). The
principle of all CECOG consensus is such that evidence-based recommendations for state-of-the-art treatment are
given upon which all participants and authors of the manuscript have to agree (Beslija S, Bonneterre J, Burstein HJ
et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771–1785). This is
of particular importance in diseases in which treatment options depend on very particular clinical and biologic variables
(Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer—update
2004. Lung Cancer 2005; 50: 129–137; Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical
treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771–1785). Since the publication of the last CECOG
consensus on the medical treatment of NSCLC, a series of diagnostic tools for the characterization of biomarkers for
personalized therapy for NSCLC as well as therapeutic options including adjuvant treatment, targeted therapy, and
maintenance treatment have emerged and strongly influenced the field. Thus, the present third consensus was
generated that not only readdresses previous disease-related issues but also expands toward recent developments in
the management of NSCLC. It is the aim of the present consensus to summarize minimal quality-oriented
requirements for individual patients with NSCLC in its various stages based upon levels of evidence in the light of
a rapidly expanding array of individual therapeutic options.
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introduction
Lung cancer is one of the most frequently occurring
malignancies in the world and represents the leading cause of
cancer-related deaths in Western countries. Non-small-cell lung
cancer (NSCLC) accounts for 80% of all lung cancer cases. In
2006, lung cancer was in incidence the third most common
cancer in Europe amounting to 386 300 cases and 12.1% of all
incident cases [1]. In the same year and geographic area, lung
cancer was the most frequent reason for death caused by
a malignancy [1]. Age-standardized incidence rates per 100 000
were 75.3 in men and 18.3 in women, whereas the
corresponding mortality rates were 64.8 in men and 15.1 in
women [1]. Smoking has been unequivocally and very strongly
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shown to be tightly associated with disease occurrence rep-
resenting the causative factor for 90% of all lung cancers [2].
Environmental tobacco smoke is a scientifically documented
concern and results in an increased risk for the development of
lung cancer [2].
Systemic therapy (chemotherapy and targeted therapy)
constitutes an essential element of multimodality therapy of
NSCLC. In early NSCLC, >80% of recurrences occur within 2
years from the time of radical surgery. However, >70% of
patients have locally advanced or metastatic disease already at
presentation and thus require systemic treatment.
method of consensus formation
panel composition
The Central European Cooperative Oncology Group (CECOG) has invited
an expert panel consisting of NSCLC experts from Europe and the United
States to generate an evidence-based consensus on all aspects of the
systemic treatment of NSCLC thus generating recommendations on how to
optimize individual treatment administered to individual patients.
literature review and analysis
In analogy to methods used for other CECOG consensus statements [2–4],
electronic and manual searches including Medline and abstracts published
in the proceedings of the most relevant topic-oriented international
meetings including conferences of the American Society of Clinical
Oncology, the European Conference of Clinical Oncology, the European
Society of Medical Oncology and the World Conference of Lung Cancer
were used for publication identification. For evidence-based clinical
recommendations, publications from peer-reviewed journals or abstracts of
randomized clinical phase III trials and meta-analyses on the systemic
treatment of NSCLC were selected for discussion and subsequent inclusion
in the manuscript. For the inclusion of manuscripts and the
acknowledgment of the results of phase III clinical trials, a significant gain
in treatment efficacy [prolongation of overall survival (OS) or progression-
free survival (PFS)] had to be reported.
Levels of Evidence [I–V] and Grades of Recommendation [A–D] as used
by the American Society of Clinical Oncology are given in square brackets
following concluding remarks summarizing each chapter.
method of consensus formation
Subgroups of three to four panel participants were coordinated by one of its
members. Each subgroup reviewed publications addressing particular aspects
relating to the medical management of NSCLC including the following: (i)
adjuvant and neoadjuvant (induction) chemotherapy, (ii) systemic therapy
for advanced disease, (iii) supportive care and (iv) molecular markers.
Each subgroup reviewed and summarized data available until December
2009 relevant to these topics. Each subgroup presented a consensus proposal
in writing. After extensive discussion among panelists via e-mail and after
a 1-day meeting on 22 January 2010 in Vienna, Austria, a consensus was
generated that represents a text upon which all panelists have agreed.
Subsequently, final text editing was completed by all authors, circulated
repeatedly between panelists by e-mail and, finally, accepted by all.
adjuvant and neoadjuvant
chemotherapy
adjuvant chemotherapy
Despite of surgery and complete surgical resection of NSCLC,
up to 60% of patients experience recurrence of disease [5–7].
Thus, adjuvant chemotherapy in these patients with completely
resected NSCLC has been proposed based on the assumption
that distant micrometastases present at the time of diagnosis
constitute the reason for recurrence of NSCLC in a considerable
proportion of patients. Several adjuvant chemotherapy trials
have been carried out [8–12]. A meta-analysis of five cisplatin-
based trials revealed an increase of the 5-year survival rate
following adjuvant chemotherapy by 5.3% [13].
Adjuvant cisplatin-based doublet chemotherapy (three to four
cycles) should be offered to patients with stage II and III disease
and may be considered for selected patients based on tumor size
with stage IB disease with adequate postoperative recovery,
absence of clinically relevant comorbidity and good performance
status (PS) within 2 months after surgery. Cisplatin should be
preferred over carboplatin and combined with a third-generation
cytotoxic drug, preferentially vinorelbine. A subgroup analysis of
the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analyses
[14] revealed a superior survival of the combination of cisplatin
with vinorelbine, as compared with other cisplatin-based
doublets [overall test of interaction P = 0.04; hazard ratio (HR)
0.80, 95% confidence interval (CI) 0.70–0.91, P < 0.001 for
LACE-vinorelbine and HR 0.95, 95% CI 0.86–1.05, P = 0.33 for
LACE-other]. Importantly, patients randomly assigned to receive
cisplatin–vinorelbine constituted the largest (41%) and the most
homogeneous subgroup in terms of cisplatin dose. Although
grade 3–4 toxicity was more common, the LACE preplanned
subanalysis confirmed a survival benefit in NSCLC of stages II
and III in patients receiving cisplatin with vinorelbine [14].
neoadjuvant (induction) chemotherapy
Full version is available at Annals of Oncology online.
conclusions.
1 Surgery remains the mainstay of treatment of early NSCLC
[Level of Evidence: I,A].
2 Adjuvant chemotherapy after complete tumor resection
should be offered to patients with stage II and III [I,A]
disease and may be considered for selected patients based on
tumor size with stage IB disease. Chemotherapy should
consist of cisplatin plus a third-generation cytotoxic drug,
preferentially vinorelbine [I,B].
3 Neoadjuvant (induction) chemotherapy may be considered
in stage III disease [II,B].
systemic therapy for advanced disease
first-line therapy
platinum-based chemotherapy. Chemotherapy improves
survival and quality of life (QoL) and palliates tumor-related
symptoms in patients with good PS [15]. The evidence of
efficacy is best documented for platinum-based regimens.
Therefore, platinum-based doublet combinations are
recommended in patients with PS of zero or one.
According to a meta-analysis, cisplatin is preferred over
carboplatin under consideration of different toxic effects of the
two drugs [16]. Cisplatinum-based treatment should be
delivered in combination with preferentially third-generation
cytotoxic drugs [16]. There is no evidence that a cisplatin dose
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of >75–80 mg/m2 delivered every 3–4 weeks might ameliorate
treatment outcome [17]. First-line cytotoxic chemotherapy
should be administered for four to six cycles but should
be stopped at disease progression. Non-platinum-based therapy
can be considered in patients who have contraindications to
platinum treatment and in unfit elderly patients.
A randomized phase III trial has indicated that pemetrexed
exerts optimal activity in nonsquamous NSCLC [18]: the
pivotal trial [18] was a noninferiority study including 1700
chemonaive patients with stage IIIB–IV NSCLC and a PS of
zero or one. Patients were randomly assigned to receive
cisplatin in combination with either gemcitabine or pemetrexed
for up to six cycles. OS was similar in both arms. However,
when analyzed by histology, patients with adenocarcinoma and
large-cell carcinoma showed significantly superior OS with
cisplatin–pemetrexed, as compared with cisplatin–gemcitabine.
The inverse was true for patients with squamous cell
carcinoma. Based on these results, cisplatin–pemetrexed was
approved by European Medicines Agency (EMA) in patients
with nonsquamous NSCLC.
Selection of first-line therapy may thus be based on clinical
criteria, histological subtype [18] and epidermal growth factor
receptor (EGFR) mutation status [21].
conclusions:
1 Platin-based doublets containing a third-generation
cytotoxic drug is the treatment of choice in patients with
advanced NSCLC, unless platinum is contraindicated [I,A].
2 Cisplatin might be preferred in patients with good PS.
3 Nonsquamous histology is a prerequisite for pemetrexed
efficacy [I,B].
4 Cisplatin doses of <75–80 mg/m2 every 3–4 weeks are
recommended [I,B].
5 Chemotherapy should be given for four to six cycles but
stopped at disease progression [II,B].
targeted therapies bevacizumab: Two randomized studies
indicated the efficacy of the antiangiogenesis compound
bevacizumab [19, 20]. The design of the pivotal intergroup
trial foresaw the continuation of bevacizumab after the
termination of chemotherapy until disease progression or
unacceptable toxicity [20]. This phase III trial that randomly
analyzed treatment efficacy by the addition of bevacizumab 15
mg/kg every 3 weeks to paclitaxel and carboplatin found
a statistically significant increase of OS as well as of PFS in the
bevacizumab-containing treatment arm [20]. Another phase
III trial (AVAIL: Avastin in Lung) on the efficacy of
bevacizumab (7.5 or 15 mg/kg every 3 weeks) combined with
gemcitabine and cisplatin confirmed the PFS benefit in
patients randomly assigned to receive bevacizumab plus
chemotherapy but did not confirm an improvement of
OS [19].
Based on presently available data, the use of bevacizumab is
not indicated in patients with squamous cell histology in whom
an increased rate of hemorrhages was observed [23].
conclusions. The addition of bevacizumab to first-line
chemotherapy (either carboplatin–paclitaxel or cisplatin–
gemcitabine) of advanced nonsquamous NSCLC provides
benefit in patients with good PS and age < 70 [I,B]. The dose of
bevacizumab may be either 7.5 or 15 mg/kg every 3 weeks
depending on the chemotherapeutic backbone.
cetuximab: In a large pivotal trial (FLEX: First-Line Erbitux
in Lung Cancer) NSCLC patients with EGFR-positive advanced
NSCLC (assessed by immunohistochemistry) were randomly
assigned to receive cisplatin plus vinorelbine with or without
cetuximab. Cetuximab was given weekly until progression of
disease [22]. Patients assigned to the cetuximab group
demonstrated a modestly longer median OS [11.3 versus 10.1
months; HR 0.871 (95% CI 0.762–0.996); P = 0.044] and
a higher response rate (RR), whereas there was no difference in
PFS. Most common cetuximab-related side-effects were acne-
like skin rash, diarrhea and infusion-related reactions. The
cetuximab-induced benefit was independent of histology
subtype, gender or smoking status. Similarly, K-RAS mutation
status was not predictive for cetuximab efficacy, whereas early
acne-like rash of any grade was associated with better outcome
[24, 25]. In another phase III study (BMS-099), the addition of
cetuximab to carboplatin plus a taxane failed to improve the
primary end point of PFS [26].
In a recent meta-analysis based on individual data of 2018
patients from four randomized phase II or III trials, the median
OS in patients who received cetuximab in addition to
chemotherapy was 10.3 months, as compared with 9.4 months
in the chemotherapy-only arm [HR 0.878 (95% CI 0.795–
0.969); P = 0.01] corresponding to an absolute benefit of 4.8%
at 1 year [27]. PFS was also more favorable for chemotherapy
plus cetuximab [HR 0.89 (95% CI 0.81–0.99); P = 0.03].
conclusions. Despite these results, the US Food and Drug
Administration label for cetuximab does not yet include
NSCLC, and the EMA did not grant its use in this indication
owing to modest benefits and associated toxicity. Nevertheless,
addition of cetuximab to a platinum-based chemotherapy
regimen is a treatment option in advanced NSCLC [I,B].
EGFR tyrosine kinase inhibitors: Four trials examined the
efficacy of EGFR tyrosine kinase inhibitors (TKIs) erlotinib or
gefitinib in combination with cytotoxic chemotherapy doublets
in the first-line setting [28–31]. All four trials found no
improvement in OS, PFS or RR with the addition of an EGFR
TKI to chemotherapy. Therefore, erlotinib or gefitinib should
not be used in combination with cytotoxic chemotherapy as
first-line treatment in unselected patients.
In contrast, the first-line use of gefitinib as single agent has
shown efficacy in patients with EGFR-activating mutations in
a large randomized phase III trial (IPASS: Iressa Pan-Asia Study)
comparing gefitinib given until disease progression with
chemotherapy consisting of paclitaxel plus carboplatin as first-
line treatment in a population specific to East Asia [21]. The
primary end point of PFS was significantly longer with gefitinib.
OS, a secondary end point, did not differ. Hematotoxicity,
alopecia, neuropathy and nausea were more pronounced in the
chemotherapy arm, whereas diarrhea and skin toxicity were
more frequent in the gefitinib arm. Patients with EGFR-
activating mutations experienced a better outcome with gefitinib,
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whereas patients without mutations had more benefit from
chemotherapy.
conclusions.
1 It is strongly recommended to test for EGFR-activating
mutations [I,A].
2 In the absence of EGFR-activating mutations, chemotherapy
remains the treatment of choice [I,A].
3 In patients with EGFR-activating mutations, treatment with
gefitinib is the preferred treatment option [I,A].
Eastern Cooperative Oncology Group PS of two. Available data
support the use of single-agent chemotherapy in patients with
Eastern Cooperative Oncology Group PS of two. However, data
are still insufficient to make a recommendation for or against
using a combination of two cytotoxic drugs for patients with PS
of two [15,32–35].
treatment in the elderly. Full version is available at Annals of
Oncology online.
conclusions: Single-agent therapy remains a reasonable
option for unfit elderly patients [I,B] [26, 36 37], although
clinical evidence does not support selection of a specific first-
line chemotherapy drug or combination based on age alone.
However, the need for enhanced supportive care should be
emphasized in this patient population.
maintenance therapy
Full version is available at Annals of Oncology online.
conclusions. The administration of pemetrexed in
nonprogressing patients with nonsquamous NSCLC
immediately after first-line platinum-based chemotherapy [I,B]
and erlotinib in patients with NSCLC who experienced stable
disease by first-line chemotherapy [I,B] constitute registered
options.
second-line systemic therapy
In patients treated with first-line chemotherapy for advanced
NSCLC, disease progression usually occurs within 3–5
months. Second-line therapy at progression palliates tumor-
related symptoms and improves survival [38]. The benefit of
second-line therapy is more likely in patients who have
responded to first-line chemotherapy and who have a good
PS [39].
Efficacy of second-line chemotherapy was first demonstrated
in a phase III trial of docetaxel against best supportive care. This
trial showed significant benefit for OS and QoL achieved by the
administration of docetaxel despite the risk of toxicity [40].
chemotherapy. Docetaxel had initially been established as
a standard in NSCLC [40, 41]. However, pemetrexed showed
similar efficacy but a more favorable toxicity profile, as
compared with docetaxel in a study originally designed to
prove noninferiority [42]. In a post hoc analysis, the benefit
achieved by pemetrexed was found to occur in patients with
nonsquamous tumors and this subsequently resulting in
a limitation change of the pemetrexed label.
targeted agents. epidermal growth factor receptor tyrosine kinase
inhibitors: Erlotinib and gefitinib were investigated for
efficacy in pretreated patients [44, 45]. A phase III study
comparing erlotinib with placebo in stage IIIB or IV NSCLC
patients who had received one to two prior combination
chemotherapy regimens and were not candidates for further
cytotoxic treatment demonstrated significant, albeit
moderate, clinical benefit of erlotinib {median OS of 6.7 and
4.7 months for erlotinib and placebo, respectively [HR 0.70
(0.58–0.85); P < 0.001]} [44]. Patients treated with erlotinib had
also improvements in pain, cough and dyspnea. The most
common side-effect of erlotinib was acneiform rash and diarrhea
(75% and 55%, respectively) although grades 3–4 toxicity
occurred in >10% of patients. High EGFR gene copy number by
FISH was the strongest predictive marker for clinical benefit from
erlotinib [46].
A similarly designed phase III trial (ISEL: Iressa Survival
Evaluation in Lung Cancer) evaluating gefitinib versus placebo
in advanced NSCLC patients in whom one or two prior
chemotherapy regimens failed did not reach significant OS
superiority [HR 0.89 (95% CI 0.77–1.02); P = 0.087] [45].
However, in preplanned subgroup analyses, OS was
significantly longer with gefitinib in never smokers and patients
of Asian ethnicity. Similarly to the BR 21 study, the clinical
benefit obtained from gefitinib was associated with high EGFR
gene copy number [47]. In a large noninferiority randomized
study (INTEREST: Iressa NSCLC Trial evaluating response and
Survival against Taxotere comparing gefitinib versus docetaxel
in previously treated advanced NSCLC patients, gefitinib was
equivalent to chemotherapy for survival and superior for the
secondary end point QoL [43].
conclusions.
1 The data from randomized trials on second-line therapy are
sufficient to recommend either a cytotoxic agent (docetaxel
for squamous NSCLC [II,B] or pemetrexed for nonsquamous
NSCLC [II,B]) or the EGFR TKI erlotinib [I,B].
2 An EGFR TKI should be strongly considered in patients with
EGFR-activating mutations in their tumors who have not
received it as first-line treatment [II,B]. Sequencing of
chemotherapy after EGFR TKIs has not been defined and
remains an important open issue.
supportive care
Full version is available at Annals of Oncology online.
molecular markers
Full version is available at Annals of Oncology online
targeted treatment options
EGFR-related biomarkers for prognosis. Ameta-analysis of several
studies failed to show a consistent correlation between EGFR
expression levels and survival [49]. Most studies have shown no
prognostic effect of EGFR expression or a slight detrimental effect.
The results for activating EGFR mutations are strikingly different.
Nearly all studies reported that patients with these mutations have
original articles Annals of Oncology
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a better outcome compared with those without these mutations,
irrespective of tumor stage and treatment [48–51].
prediction of outcome of EGFR-targeted therapy: About 10%
of NSCLC patients in a Western population and 30%–50% in
East Asia have EGFR-activating mutations. A randomized
phase II study showed that in patients with EGFR-activating
mutations, the median PFS was 18.2 months with erlotinib
compared with 4.9 months with the alteration of chemotherapy
and erlotinib. In contrast, the chemotherapy arm had a better
median PFS in patients without an EGFR-activating mutation
[52]. There is no evidence that EGFR-activating mutations
predict for superior outcome following cetuximab therapy [25].
While K-RAS mutation has been demonstrated to be a negative
predictor in EGFR inhibition in patients with metastatic
colorectal cancer, its role in NSCLC patients is still under debate.
EML4-ALK fusion. The fusion gene EML4-Anaplastic
Lymphoma Kinase (ALK) was first reported in NSCLC only
a few years ago [53]. A clinical dose-escalation phase I study
with an oral MET and ALK inhibitor PF-02341066 showed for
NSCLC patients with tumors harboring an activating ALK gene
fusion an objective RR of 64% and a disease control rate of 90%
[54]. Although the ALK fusion either with EML4 or with other
fusion partners is relatively infrequent in NSCLC (4%–5%),
there still is a substantial number of patients who might have
a significant clinical benefit from this well-tolerated therapy [55].
conclusions:
1 EGFR mutations predict a better response to EGFR TKIs (i.e.
gefitinib) compared with chemotherapy as first-line therapy
in advanced NSCLC. Thus, EGFR mutation testing should be
encouraged before treatment decision [I,A].
2 K-RAS mutation predicts a low response to EGFR TKIs, but
a significant association with survival was demonstrated for
neither EGFR TKI nor EGFR-directed antibody therapy.
Testing should not be recommended as a basis for treatment
decisions in routine practice.
3 Patients with EML4-ALK fusion tumors benefit from specific
targeted therapy against EML4-ALK fusion. The role of
routinely carried out EML4-ALK fusion testing for clinical
practice is awaiting the results from ongoing clinical trials.
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